Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Experimental Sepsis

Not Applicable

• Conditions: Sepsis
• Interventions: Drug: oxygen; Drug: Sevoflurane; Drug: Isoflurane

• Registration Number: NCT02185118
• Lead Sponsor: Air Force Military Medical University, China

Brief Summary

Sepsis is a major cause of death in intensive care units. Despite the investigators improved understanding, which has reduced the risk of dying with sepsis, the number of people who die each year continues to increase due to an overall increase in the number of cases.In our previous study, the investigators have showed that 100% oxygen or 0.5 minimum alveolar concentration (MAC) isoflurane/sevoflurane in 60% oxygen protect mouse macrophage cell line against in-vitro sepsis induced by lipopolysaccharide (LPS).

In this study, the investigator hypothesized that treatment of 100% oxygen or 0.5 MAC isoflurane/sevoflurane in 60% oxygen protected against clinical in-vitro models of sepsis induced by LPS or plasma from septic patients.

Detailed Description

100% oxygen or 0.5 MAC isoflurane/sevoflurane in 60% oxygen would inhibit increases of tumor necrosis factor (TNF)-alpha, interleukin-1beta, interleukin-6 in the cell culture supernatant after stimulation of LPS or plasma from septic patients, and also inhibit the nuclear location of nuclear factor-kappa B p65 subunit.

Study Timeline

• Study Start: 2014-06
• Study First Submitted: 2014-06-20
• Status Verified: 2014-07
• Study First Submitted QC: 2014-07-06
• Last Update Submitted: 2014-07-06
• Study First Posted: 2014-07-09
• Last Update Posted: 2014-07-09
• Primary Completion: 2018-06
• Study Completion: 2018-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Human PBMCs were only isolated from the adult patients without sepsis/SIRS/infectious diseases.
• The plasma for induction of clinical in-vitro sepsis, was only isolated from adult patients with sepsis.

Exclusion Criteria

• Patients who had been selected for other clinical trials in the 3 months before.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
oxygen plus isoflurane/sevoflurane	oxygen	All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection. The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients.
oxygen plus isoflurane/sevoflurane	Isoflurane	All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection. The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients.
oxygen plus isoflurane/sevoflurane	Sevoflurane	All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection. The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients.

Primary Outcome Measures

Name	Time	Method
Subcellular location of Nuclear Factor-KAPPA B p65 subunit	within 10 hours after the intervention

Secondary Outcome Measures

Name	Time	Method
tumor necrosis factor-alpha	within 10 hours after the intervention
interleukin- 1 beta	within 10 hours after the intervention
interleukin 6	within 10 hours after the intervention

Trial Locations

Locations (1)

Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University,; 🇨🇳 Xi'an, Shaanxi, China